Interview with Trevor Millar, Advisor, NeonMind Biosciences

Advisor to NeonMind Biosciences, Trevor Millar, gives insight on how the company is tackling the obesity epidemic.

Advisor to NeonMind Biosciences, Trevor Millar, gives insight on how the company is tackling the obesity epidemic.

Episode Summary

In this episode of the Psychedelic Spotlight podcast, we speak with Trevor Millar, a distinguished Advisor to NeonMind Biosciences, an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions.

In our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based treatments NeonMind is currently focused on developing to help tackle this very serious health condition. Obesity is one of the more prevalent health conditions today affecting millions of individuals worldwide. The World Health Organization has claimed that obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese.

*You can find NeonMind Biosciences trading on the Canadian securities exchange under the symbol $NEON. To learn more about the company, visit their website: NeonMindBiosciences.com